DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
Business Wire•19/10/2026•08:00 ET
0
Key Highlights
- ➤November 24 webinar will present preliminary interim topline results from two Phase 2 FGR cohorts
- ➤First two cohorts enrolled 12 participants in investigator-sponsored early-onset FGR trial
- ➤DM199 trial evaluates repeated subcutaneous dosing up to 15 µg/kg until delivery
- ➤Phase 2 FGR trial enrollment commenced in June 2026 at Tygerberg Hospital
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
* Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026
Get started
Create a free account to read the full story.